巨生醫 (6827.TW) 2025Q4 financial report shows operating profit of -55.82M TWD, with a YoY growth rate of 39.28%, showing strong growth and outstanding core business performance, with significantly improved operational efficiency. It is recommended to also monitor the structure of operating profit, recent revenue, and gross margin, and compare with industry peers. With Growin AI Value Analysis, verify whether core profitability is fundamentally supported. If both operating profit and business performance continue to grow steadily, the company’s future is worth anticipating.